Every 8-K that Alto Neuroscience Inc. (ANRO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ANRO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ANRO filings page.
Alto Neuroscience, Inc. (ANRO) announced a leadership change effective August 26, 2026. The Board promoted Nicholas C. Smith, previously Chief Financial Officer and Chief Business Officer, to President and Chief Financial Officer. Amit Etkin, M.D., Ph.D. remains Chief Executive Officer and continues to serve as the principal executive officer, while Mr. Smith is the principal financial officer.
Under a new Promotion and Retention Agreement, Mr. Smith is entitled to a cash Retention Payment totaling $6,000,000, with $3,000,000 payable within ten days of August 26, 2026 and $3,000,000 on the twelve-month anniversary of that date, subject to standard deductions and withholdings. If his employment ends for any reason, or for Cause by the company, before the two-year Retention Date, any unpaid portion is forfeited and any paid portion is subject to recoupment within 30 days, except when the company terminates him without Cause or his employment ends due to death or Disability, in which case any unpaid portion will be paid.
Alto Neuroscience, Inc. reported second quarter 2026 results and pipeline updates focused on its lead program ALTO-207 for treatment-resistant depression. The company expanded ALTO-207 development to include a planned Phase 3 monotherapy trial in addition to an ongoing potentially registrational Phase 2b adjunctive trial, with topline Phase 2b data expected in 2H 2027. Independent data published in Nature Medicine reinforced the dopaminergic mechanism underlying ALTO-207 and showed significant effects on anhedonia. Enrollment continues in Phase 2b trials of ALTO-300 in major depressive disorder and ALTO-100 in bipolar depression, with data expected in 2027.
Alto completed an approximately $100 million registered direct offering in July 2026, resulting in pro forma cash of about $338 million, which the company expects to fund planned operations through 2030. As of June 30, 2026, cash, cash equivalents, and restricted cash were $244.2 million. For the quarter, research and development expenses rose to $22.1 million and general and administrative expenses to $7.0 million, leading to a net loss of $27.6 million compared to $17.7 million a year earlier.
Alto Neuroscience, Inc. entered into an underwriting agreement with BofA Securities, as representative of several underwriters, to issue and sell 3,776,436 shares of common stock in an underwritten registered direct offering under an effective shelf registration statement. The shares are priced at $26.48 per share, and the company estimates net proceeds of approximately $93.9 million after underwriting discounts, commissions and offering expenses.
The closing is expected on July 14, 2026, subject to customary conditions. Alto Neuroscience plans to use the net proceeds, together with existing cash and cash equivalents, to accelerate and expand clinical development of ALTO-207, including a planned additional Phase 3 monotherapy trial in treatment-resistant depression, and for general working capital.
Alto Neuroscience, Inc. reported a preliminary estimate of its cash, cash equivalents and restricted cash of approximately $244.2 million as of June 30, 2026. This figure is based on management’s estimates, has not been audited, reviewed or compiled by the independent registered public accounting firm, and may change after completion of accounting procedures for the quarter ended June 30, 2026; any differences may be material.
The company also outlined a pipeline update, stating that it intends to accelerate and expand clinical development of its ALTO-207 program, including conducting an additional planned Phase 3 trial of ALTO-207 as monotherapy for treatment-resistant depression.
Alto Neuroscience, Inc. appointed Andrew Miller, Ph.D. to its Board of Directors as a Class III director, filling a seventh board seat for a term ending at the 2027 annual stockholder meeting. He was also named to the Nominating and Corporate Governance Committee and deemed independent under NYSE and SEC rules.
As a non-employee director, Dr. Miller will receive an initial stock option for up to 48,200 shares or options valued at up to $400,000 by Black‑Scholes, plus ongoing annual option grants and cash retainers for board and committee service under the company’s Non-Employee Director Compensation Policy.
Alto Neuroscience, Inc. reported results from its 2026 annual stockholder meeting. Of 31,945,516 common shares outstanding as of the record date, 26,762,809 shares, or about 83.77%, were represented, giving the company a strong quorum for voting.
Stockholders elected two Class II directors: Raymond Sanchez, M.D. received 23,133,161 votes for and 31,432 withheld, while Gwill York received 12,385,501 for and 10,779,092 withheld, with 3,598,216 broker non-votes for each. They ratified Deloitte & Touche LLP as independent registered public accounting firm for the year ending December 31, 2026, with 26,727,215 votes for. Stockholders did not approve an amendment and restatement of the 2024 Equity Incentive Plan related to treating pre-funded warrants like common shares for the plan’s evergreen share reserve, but did approve a similar amendment and restatement of the 2024 Employee Stock Purchase Plan.
Alto Neuroscience reported first quarter 2026 results, combining deeper investment in its precision psychiatry pipeline with a much stronger balance sheet. Cash, cash equivalents, and restricted cash rose to about $264.2 million as of March 31, 2026 from $177.0 million, reflecting net proceeds of roughly $115 million from a March 2026 PIPE financing.
The company advanced several key programs, including initiation of a potentially registrational Phase 2b trial of ALTO-207 in treatment-resistant depression, new supportive biomarker data for ALTO-101, and ongoing Phase 2b trials for ALTO-300 and ALTO-100 with enhanced patient-quality controls. Alto now expects topline data in 2027 across these mid‑ to late‑stage trials and guides its current cash runway to fund operations, including a potential NDA submission for ALTO-207, through 2029.
Operating expenses increased as R&D spending roughly doubled year over year, driving a larger net loss of $26.2 million (or $0.80 per share) for the quarter compared with $15.2 million (or $0.56 per share) a year earlier.
Alto Neuroscience reported topline results from a Phase 2 proof-of-concept trial of ALTO-101 in cognitive impairment associated with schizophrenia. The drug did not achieve statistical significance on primary EEG or cognitive endpoints versus placebo, though directional EEG improvements were seen.
In a more cognitively impaired subgroup, ALTO-101 showed nominally significant benefits on the theta-ITC EEG measure, and several EEG signals improved between day 5 and day 10. ALTO-101 was well tolerated, with nausea and vomiting rates similar to placebo, suggesting its pharmacokinetic profile may address a key limitation of the PDE4 inhibitor class.
Alto has created a modified-release, once-daily oral formulation of ALTO-101 with improved pharmacokinetics and tolerability and plans to seek partners for this program rather than independently advancing ALTO-101 in CIAS. The company is prioritizing its lead program, ALTO-207 for treatment-resistant depression, with a Phase 2b trial in about 178 adults expected to start in the first half of 2026, supported by prior positive Phase 2a data. Management highlighted a cash position of $275 million and multiple advancing clinical programs.
Alto Neuroscience is raising new capital through a private placement of 2,900,000 common shares and pre-funded warrants to purchase 3,100,000 shares at $20.00 per share, for gross proceeds of about $120 million before expenses. The pre-funded warrants have a $0.0001 exercise price and do not expire, with a beneficial ownership cap that cannot exceed 19.9% without advance notice.
The company entered a registration rights agreement to register for resale both the shares sold and the shares underlying the pre-funded warrants, with liquidated damages of 1.0% of each investor’s purchase amount per 30-day period if filing or effectiveness deadlines are missed, subject to caps. Jefferies, BofA Securities, TD Cowen, Stifel, William Blair, and Baird are acting as placement agents.
Alto expects to use the proceeds primarily to fund development of its ALTO-207 program in treatment resistant depression, including a planned Phase 3 trial and potential NDA submission, as well as for working capital and general corporate purposes. After the expected net proceeds, Alto estimates cash and cash equivalents would have been about $275 million as of February 28, 2026.
Alto Neuroscience reported a full-year 2025 net loss of $63.2 million, or $2.19 per share, driven by research and development spending as its pipeline advances. Research and development expenses were $45.6 million and general and administrative expenses were $20.7 million, both slightly lower than 2024.
Cash, cash equivalents, and restricted cash totaled about $177 million as of December 31, 2025, which the company expects will fund planned operations into 2028. Alto highlighted progress across its precision psychiatry pipeline, including the acquisition and accelerated development of ALTO-207 for treatment-resistant depression, Fast Track status for ALTO-101 in CIAS, and multiple Phase 2b data readouts expected in 2026.
Alto Neuroscience, Inc. filed a Form 8-K stating that it reported financial results for the fiscal quarter ended September 30, 2025. The company released these quarterly results in a press release dated November 12, 2025, which is furnished as Exhibit 99.1 and incorporated by reference.
The Form 8-K clarifies that the financial information, including the press release, is being furnished rather than filed under the Exchange Act and is not subject to certain liability provisions, unless specifically incorporated into other SEC filings.
Alto Neuroscience entered into a private placement on October 19, 2025, agreeing to sell 3,832,263 shares of common stock and issue pre-funded warrants exercisable for 4,622,251 shares at a purchase price of $5.914 per share, for anticipated gross proceeds of approximately $50.0 million before expenses. The pre-funded warrants carry a $0.0001 per share exercise price and remain outstanding until exercised, subject to a beneficial ownership cap that cannot exceed 19.9%.
The company agreed to file registration statements within 45 days after closing to register the resale of the shares and the warrant shares and to achieve effectiveness within a set period thereafter. Separately, Alto terminated its $75 million at-the-market offering agreement effective October 30, 2025, and did not sell any shares under that program.
Alto Neuroscience reported results for the fiscal quarter ended June 30, 2025; a press release is furnished as Exhibit 99.1 to this report.
The company’s Board increased from five to six members and appointed Ramiro (Raymond) Sanchez, M.D., age 64, as an independent Class II director with a term expiring at the 2026 Annual Meeting. Dr. Sanchez brings more than 20 years of life sciences experience, including roles as Chief Medical Officer and senior global clinical development positions, and currently serves as a Senior Advisor at Bain Capital Life Sciences.
Under the Non-Employee Director Compensation Policy Dr. Sanchez will receive an initial option grant to purchase 30,574 shares vesting in equal monthly installments over three years, an annual option grant of 15,287 shares, a $40,000 annual cash retainer plus a $5,000 annual NCGC retainer, and standard indemnification. The Board also rebalanced director classes and updated committee memberships.
Alto Neuroscience (NYSE:ANRO) filed an 8-K announcing a material clinical milestone. A press release (Ex. 99.1) reports positive pharmacodynamic results and biomarker identification from an exploratory Phase 2 proof-of-concept trial of lead candidate ALTO-203.
Key points:
- Phase 2 study delivered a favorable pharmacodynamic signal; no numerical efficacy or safety data were released.
- New biomarker is positioned as a tool for future patient selection and trial design.
- No changes to strategy, guidance, or capital structure disclosed.
The update may de-risk ALTO-203 ahead of planned later-stage studies and could influence investor sentiment.